Phase 2 study of letrozole, abemaciclib, and metformin in estrogen receptor (ER)–positive recurrent endometrial cancer (EC). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
DM1 cohort recruitment completion in Q4 2025, topline data in mid-2026, and potential BLA filing for z-basivarsen in late ...
Japan's Sosei Group Corp said on Monday it is allying with a U.S. biotech run by former Novartis AG executives to commercialise a neurological drug pipeline.
In the Phase III FIBRONEER-IPF study, Jascayd demonstrated significant lung capacity improvements over placebo.
Funded entirely by taxpayer dollars, this first-of-its-kind drug targets cellular metabolism to promote tissue repair of multiple organs.
(Reuters) -An agreement was reached on all the provisions and implementation mechanisms of the first phase of the Gaza ceasefire agreement, which will lead to ending the war, the release of Israeli ...
Pharmaceutical Technology on MSN
Boehringer’s Jascayd nets first FDA IPF approval in over 10 years
Boehringer Ingelheim’s Jascayd (nerandomalist) has got the US Food and Drug Administration (FDA) nod in idiopathic pulmonary fibrosis (IPF), making it the first drug to be approved in this indication ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results